Medgend Icon







discontinued


Cancer

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body. Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation. NIH: National Cancer Institute

Cancer FDA Approved Drugs

ABRAXANE [PaclitaxelC47H51NO14]
RX
-
100mg/vial (iv (infusion) for suspension)
Abraxis BioscienceJan 7, 2005
  • Treatment of breast cancer.
  • Treatment of lung cancer.
  • Treatment of pancreatic cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ABSTRAL [Fentanyl CitrateC22H28N2OC6H8O7]
RX
-
eq 0.1mg base (sublingual tablet)
eq 0.2mg base (sublingual tablet)
eq 0.3mg base (sublingual tablet)
eq 0.4mg base (sublingual tablet)
eq 0.6mg base (sublingual tablet)
eq 0.8mg base (sublingual tablet)
Sentynl Theraps IncJan 7, 2011
  • Management of breakthrough pain in patients with cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

AFINITOR [EverolimusC53H83NO14]
RX
-
10mg (oral tablet)
2.5mg (oral tablet)
7.5mg (oral tablet)
NovartisMar 30, 2009
  • Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
  • Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic.
  • Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected..
  • Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ALUNBRIG [BrigatinibC29H39ClN7O2P]
RX
-
30mg (oral tablet)
90mg (oral tablet)
AriadApr 28, 2017
  • Treatment of patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) who have progressed on or are intolerant to crizotinib.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CAMPTOSAR [Irinotecan HydrochlorideC33H38N4O6ClH3H2O]
RX
-
100mg/5ml (20mg/ml) (injection injectable)
300mg/15ml (20mg/ml) (injection injectable)
40mg/2ml (20mg/ml) (injection injectable)
Pfizer IncJun 14, 1996
  • Use in combination with 5-fluorouracil and leucovorin for the treatment of metastatic colorectal cancer where the dose of leucovorin is at least 200mg per square meter.
  • Use of irinotecan in combination with 5-fluorouracil and leucovorin for the treatment of metastatic colorectal cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

COMETRIQ [Cabozantinib S-malateC28H24FN3O5C4H6O5]
RX
-
eq 20mg base (oral capsule)
eq 80mg base (oral capsule)
ExelixisNov 29, 2012
  • Method of treating medullary thyroid cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CYSVIEW KIT [Hexaminolevulinate HydrochlorideC11H21NO3ClH]
RX
-
100mg/vial (intravesical for solution)
Photocure AsaMay 28, 2010
  • Detection of non-muscle invasive papillary cancer of the bladder by photodynamic cystoscopy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ELIGARD [Leuprolide AcetateC59H84N16O12C2H4O2]
RX
-
22.5mg/vial (subcutaneous injectable)
30mg/vial (subcutaneous injectable)
45mg/vial (subcutaneous injectable)
7.5mg/vial (subcutaneous injectable)
Tolmar TherapJul 24, 2002
  • Method of treating cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ERIVEDGE [VismodegibC19H14Cl2N2O3S]
RX
-
150mg (oral capsule)
GenentechJan 30, 2012
  • Method of using vismodegib to treat cancer in a mammal.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

EVISTA [Raloxifene HydrochlorideC28H27NO4SClH]
RX
-
60mg (oral tablet)
LillyDec 9, 1997
  • Prevention of osteoporosis in postmenopausal women.
  • Use for prevention of breast cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FASLODEX [FulvestrantC32H47F5O3S]
RX
-
50mg/ml (intramuscular injectable)
AstrazenecaApr 25, 2002
  • Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
  • Treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbococlib in women with disease progression after endocrine therapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FENTORA [Fentanyl CitrateC22H28N2OC6H8O7]
RX
-
eq 0.1mg base (buccal, sublingual tablet)
eq 0.2mg base (buccal, sublingual tablet)
eq 0.4mg base (buccal, sublingual tablet)
eq 0.6mg base (buccal, sublingual tablet)
eq 0.8mg base (buccal, sublingual tablet)
CephalonSep 25, 2006
  • Management of breakthrough pain in patients with cancer by buccal or sublingual administration of fentanyl.
  • Management of breakthrough pain in patients with cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FIRMAGON [Degarelix AcetateC82H103ClN18O16C2H4O2H2O]
RX
-
eq 120mg base/vial (subcutaneous powder)
eq 80mg base/vial (subcutaneous powder)
FerringDec 24, 2008
  • Gnrh antagonist indicated for treatment of patients with advanced prostate cancer.
  • Method of treating prostate cancer.
  • Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

GILOTRIF [Afatinib DimaleateC24H25ClFN5O32C4H4O4]
RX
-
eq 20mg base (oral tablet)
eq 30mg base (oral tablet)
eq 40mg base (oral tablet)
Boehringer IngelheimJul 12, 2013
  • Treatment of cancer.
  • Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HALAVEN [Eribulin MesylateC40H59NO11CH4O3S]
RX
-
1mg/2ml (0.5mg/ml) (intravenous solution)
Eisai IncNov 15, 2010
  • Treatment of patients with metastatic breast cancer.
  • Treatment of patients with unresectable or metastatic liposarcoma.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

IBRANCE [PalbociclibC24H29N7O2]
RX
-
100mg (oral capsule)
125mg (oral capsule)
75mg (oral capsule)
Pfizer IncFeb 3, 2015
  • Treating hr-pos., her2-neg. advanced or metastatic breast cancer with palbociclib in combo with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression after endocrine therapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

IRESSA [GefitinibC22H24ClFN4O3]
RX
-
250mg (oral tablet)
Astrazeneca PharmsJul 13, 2015
  • First-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

IXEMPRA KIT [IxabepiloneC27H42N2O5S]
RX
-
15mg/vial (iv (infusion) injectable)
45mg/vial (iv (infusion) injectable)
R-pharm Us LlcOct 16, 2007
  • A method of treating cancer in a patient comprising administering ixabepilone or pharmaceutical compositions comprising ixabepilone.
  • Method of treating breast cancer by administering ixabepilone; a method of treating a cancer responsible to microtubule stabilization by administering ixabepilone.
  • Method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent.
  • Method of treating cancer, iv admin, lyophylized ixabepilone diluted, every week or 3 weeks; lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml.
  • Method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt.
  • Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JEVTANA KIT [CabazitaxelC45H57NO14]
RX
-
60mg/1.5ml (40mg/ml) (iv (infusion) solution)
Sanofi Aventis UsJun 17, 2010
  • Treatment in combination with a corticoid such as prednisone of prostate cancer previously treated iwth docetaxel.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

KISQALI [Ribociclib SuccinateC23H30N8OC4H6O4]
RX
-
eq 200mg base (oral tablet)
Novartis Pharms CorpMar 13, 2017
  • In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

KISQALI FEMARA CO-PACK (COPACKAGED) [LetrozoleC17H11N5 : Ribociclib SuccinateC23H30N8OC4H6O4]
RX
-
2.5mg,n/a : n/a,eq 200mg base (oral tablet, tablet)
Novartis Pharms CorpMay 4, 2017
  • In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LAZANDA [Fentanyl CitrateC22H28N2OC6H8O7]
RX
-
eq 0.1mg base (nasal spray, metered)
eq 0.3mg base (nasal spray, metered)
eq 0.4mg base (nasal spray, metered)
Depomed IncJun 30, 2011
  • Management of breakthrough pain in cancer patients 18 years of age and older who are receiving and tolerant to opioid therapy for their underlying persistent cancer pain.
  • Management of breakthrough pain in patients with cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LENVIMA [Lenvatinib MesylateC21H19ClN4O4CH4O3S]
RX
-
eq 10mg base (oral capsule)
eq 4mg base (oral capsule)
Eisai IncFeb 13, 2015
  • Method for treating thyroid carcinoma including differentiated thyroid cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LONSURF [Tipiracil HydrochlorideC9H11ClN4O2ClH : TrifluridineC10H11F3N2O5]
RX
-
eq 6.14mg base : 15mg (oral tablet)
eq 8.19mg base : 20mg (oral tablet)
Taiho OncologySep 22, 2015
  • Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LUPRON DEPOT [Leuprolide AcetateC59H84N16O12C2H4O2]
RX
-
11.25mg/vial (injection injectable)
22.5mg/vial (injection injectable)
3.75mg (injection injectable)
30mg/vial (injection injectable)
45mg/vial (injection injectable)
7.5mg/vial (injection injectable)
Abbvie Endocrine IncMar 7, 1997
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LYNPARZA [OlaparibC24H23FN4O3]
RX
-
50mg (oral capsule)
Astrazeneca PharmsDec 19, 2014
  • Treatment of brca mutated ovarian cancer using parp inhibitor.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NINLARO [Ixazomib CitrateC20H23BCl2N2O9]
RX
-
eq 2.3mg base (oral capsule)
eq 3mg base (oral capsule)
eq 4mg base (oral capsule)
Millennium PharmsNov 20, 2015
  • Method for treating cancer, including multiple myeloma.
  • Method for treating multiple myeloma with one or more other therapeutic agents.
  • Method for treating multiple myeloma.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ONIVYDE [Irinotecan HydrochlorideC33H38N4O6ClH3H2O]
RX
-
eq 43mg base/10ml (eq 4.3mg base/ml) (iv (infusion) injectable, liposomal)
Ipsen IncOct 22, 2015
  • Treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
  • Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele.
  • Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
  • Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
  • Treatment of pancreatic cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

RUBRACA [Rucaparib CamsylateC19H18FN3OC10H16O4S]
RX
-
eq 200mg base (oral tablet)
eq 250mg base (oral tablet)
eq 300mg base (oral tablet)
Clovis Oncology IncDec 19, 2016
  • A method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SPRYCEL [DasatinibC22H26ClN7O2SH2O]
RX
-
100mg (oral tablet)
140mg (oral tablet)
20mg (oral tablet)
50mg (oral tablet)
70mg (oral tablet)
80mg (oral tablet)
Bristol Myers SquibbMay 30, 2008
  • A method for the treatment of a protein tyrosine kinase-associated disorder.
  • A method for the treatment of cancer.
  • A method for treatment of a cancer, wherein the cancer is chronic myelogenous leukemia.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TAGRISSO [Osimertinib MesylateC28H33N7O2CH4O3S]
RX
-
eq 40mg base (oral tablet)
eq 80mg base (oral tablet)
Astrazeneca PharmsNov 13, 2015
  • Treatment of patients with metastatic epidermal growth factore receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TARCEVA [Erlotinib HydrochlorideC22H23N3O4ClH]
RX
-
eq 100mg base (oral tablet)
eq 150mg base (oral tablet)
eq 25mg base (oral tablet)
Osi PharmsNov 18, 2004
  • First-line treatment of locally advanced unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
  • First-line treatment of metastatic non smal-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test.
  • Maintenance treatment in patients with locally advanced or metastatic nsclc who have not progressed on 1st-line treatment wth platinum-based chemotherapy.
  • Maintenance treatment of patients with locally advanced or metastatic nsclc whose disease has not progressed after four cycles platinum-based chemotherapy.
  • Treatment of locally advanced or metastatic non small-cell lung cancer (nsclc) after failure of at least one prior chemotherapy regimen.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TYKERB [Lapatinib DitosylateC29H26ClFN4O4S2C7H8O3SH2O]
RX
-
eq 250mg base (oral tablet)
Novartis Pharms CorpMar 13, 2007
  • Treatment of patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received prior therapy including anthracycline, a taxane and trastuzumab.
  • Treatment of patients with breast cancer whose tumors overexpress the her2 receptor.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

VARUBI [Rolapitant HydrochlorideC25H26F6N2O2ClHH2O]
RX
-
eq 90mg base (oral tablet)
Tesaro IncSep 1, 2015
  • Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XALKORI [CrizotinibC21H22Cl2FN5O]
RX
-
200mg (oral capsule)
250mg (oral capsule)
Pf Prism CvAug 26, 2011
  • Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XTANDI [EnzalutamideC21H16F4N4O2S]
RX
-
40mg (oral capsule)
AstellasAug 31, 2012
  • The treatment of patients with metastatic castration-resistant prostate cancer (crpc)..
  • The treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ZYKADIA [CeritinibC28H36ClN5O3S]
RX
-
150mg (oral capsule)
Novartis Pharms CorpApr 29, 2014
  • Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk).
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ZYTIGA [Abiraterone AcetateC26H33NO2]
RX
-
250mg (oral tablet)
500mg (oral tablet)
Janssen BiotechApr 28, 2011
  • Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who had received prior docetaxel chemotherapy.
  • Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
  • Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK


WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.



WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Felter's Materia Medica on Cancer

CONDURANGO
   The bark of Gonolobus Cundurango, Triana (Marsdenia Condurango, Reichenbach) (Nat. Ord. Asclepiadaceae). South America, especially Ecuador. Common... / ...Therapy.—A drug of considerable power, introduced into medicine in 1871 as a cure for syphilis and cancer of the stomach, in both of which it has but an unsustained reputation. It is thought, however... / ...powerfully upon the nervous system, inducing in animals, impaired appetite, vomiting, ptyalism, muscular weakness, convulsions, and paralysis.1

CONIUM
   .... Therapy.—External. Locally applied extract of conium, or the powdered drug, relieves the pain of cancerous growths and ulcers. Locke advised, Rx. English Extract of Conium, 2 drachms; Petrolatum, 6......east; therefore it is safe to assume that such nodules as are influenced by conium are probably not cancerous, but more than likely of a strumous character. At any rate we are not justified in delayin...1

ECHINACEA
   The dried root of Brauneria angustifolia, Linné (Echinacea angustifolia [DeCandolle], Heller). (Nat. Ord. Compositae.) In rich prairie soils of... / ...ulcerations, fetid discharges from the ears, and in gangrene. While not wholly masking the odor of cancer and gangrene it reduces it greatly, much to the comfort of the sick and the attendants. Echin... / ...cent solution to full strength echinacea or echafolta may be freely used, syringing the channels with it. This gives great relief from pain 1

EUCALYPTUSEUAN12
   The leaves of Eucalyptus Globulus, Labillardiere. Collected from the older parts of the tree. (Nat. Ord. Myrtaceae.) A native tree of Australia;... / ...ic diseases of the bronchopulmonic tract, with fetor, relaxation and abundant secretions. Used upon cancerous surfaces they mask the fetid odor and give some relief from pain. The following is an idea... / ...Used according to indications as given above, eucalyptus is a very satisfactory and pleasant medicine. It is best given in syrup or glycerin.1

FICUS
   The fleshy receptacle of Ficus Carica, Linné bearing fruit on its inner surface. (Nat. Ord. Moraceae.) Persia and Asia Minor; cultivated in all... / .... The great surgeon, Billroth, employed a poultice of dried figs and milk to overcome the stench of cancerous and fetid ulcers. Internal. Nutritive, demulcent, and aperient. Figs are frequently resort... / ...dates, raisins, prunes, and senna leaves. This is wrapped in tinfoil, and sliced off and eaten according to the requirements of the individual.1

TRIFOLIUM
   The blossoms of Trifolium Pratense, Linné (Nat. Ord. Leguminosae). Cultivated everywhere. Common Name: Red Clover. Principal Constituents.—Resins and... / ...gnant neoplasms. Though by no means curative in carcinoma, patients who have been operated upon for cancer are slower in redeveloping the growths when given tincture of trifolium daily.1


WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Physician's Materia Medica on Cancer

ARBOR VITAE
   The leafy twigs of THUJA OCCIDENTALIs, Lin. Antiperiodic, iebrifuge, emmenagogue, alterative, anthelmintlo, anti-scorbutic. Used locally as an antiseptic and stimulant wash for cancerous ul cerations; internally in malarial fevers, chronic bronchitis, scurvy and rheumatism.2

CANCER-ROOTCONOP
   The root of LEPTAMNIUM VIRGINIANUM, (L.) Raf. an efficient astringent.2

CONIUM (Poison Hemlock)
   The immature fruit, also the leaves (unoflicial), oi CONIUM MACULATUM, Lin. Sedative, discutient, antispasmodic, anaphro disiac. Prescribed in cutaneous diseases, cancer and scrofulous indurations for its resolvent action, and in tetanus, chorea and acute mania as an antispasmodic and sedative.2


References

1) Felter, Harvey Wickes, 1922, The Eclectic Materia Medica, Pharmacology and Therapeutics, Cincinnati, Ohio.
2) Nelson, Baker & Co., 1904, Physician's Handy Book of Materia Medica and Therapeustics, Detroit, Michigan.